Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
caspase pathway Galanin a amino acid peptide was first isola
2022-04-18
Galanin, a 29/30-amino-acid peptide, was first isolated in 1983 from porcine intestine by Tatemoto and collaborators [70]. It is widely distributed throughout the central and peripheral nervous systems as well as other tissues. It is involved in a wide range of physiological functions, such as modul
-
Albumin is the major carrier of free fatty acids FFAs
2022-04-18
Albumin is the major carrier of free fatty acids (FFAs) in plasma [59], and harbours seven binding sites that are common to FFAs with a range of chain-lengths (C10-C18) across its three domains (Fig. 1a) [60,61]. In vitro, saturated, mono- and poly-unsaturated FFAs, with chain lengths ranging from C
-
Conclusions br Author information The obtained models
2022-04-18
Conclusions Author information The obtained models of complexes of FPR2 with most of the described compounds are freely available at the author’s web site: http://www.biomodellab.eu/models/. Acknowledgements This work was partly done at the Interdisciplinary Centre for Mathematical and Compu
-
Reports described a range of synthetic GPR
2022-04-18
Reports described a range of synthetic GPR40 agonists with desirable safety and efficacy profiles, compared with existing antidiabetic therapies such as insulin and sulfonylureas [[20], [21], [22], [23], [24], [25], [26], [27], [28]]. Among them, several small molecules were tested in the clinical t
-
Chemotherapeutic approaches to glioblastoma which are highly
2022-04-18
Chemotherapeutic approaches to glioblastoma, which are highly invasive, are still largely unsuccessful and have only a minimal impact on patients’ survival rate . New agents that target the specific molecular aberrations in the tumors are presently being investigated for their efficacy against this
-
br Declarations of interest br Founding information
2022-04-18
Declarations of interest Founding information This work was partially supported by the New Energy and Industrial Technology Development Organization (NEDO) Japan [grant number P03043]; and Grants-in-Aid for Scientific Research [grant number 16H00738 to H.M.] from the Japan Society for the Prom
-
The conjugated gold is an essential part
2022-04-16
The conjugated gold is an essential part of rapid test kits. For this PIs-IC strip the gold nanoparticles were conjugated with an optimal concentration of antibody to produce a stable nanoparticle solution (Fig. 3). From TEM images it became obvious that the colloid gold contained particles of diffe
-
To efficiently develop bioactive ligands even
2022-04-16
To efficiently develop bioactive ligands even if the structural information of the target protein is unknown, we have presented a three-dimensional structural diversity-oriented strategy based on structural properties of a chiral cyclopropane. Our strategy has allowed us to design and synthesize a s
-
br Acknowledgements and disclosures This work was
2022-04-16
Acknowledgements and disclosures This work was supported in part by the National Institutes of Health (R01 HL-131673-01A1) and the Veterans Administration (BX-002539-01), United States. The authors have nothing to disclose concerning any conflict of interest. Introduction Adaptations are ofte
-
The inhibitory activities of new compounds
2022-04-16
The inhibitory activities of new compounds against P. aeruginosa were determined in both DTSB media supplemented with heme or free iron and LB media (Table 1). The MIC50 values of the compounds ranged from 42 to 260 μg/mL in DTSB medium and from 26 to 230 μg/mL in LB medium. Among these new inhibito
-
br Conclusion The development discovery of compounds targeti
2022-04-16
Conclusion The development/discovery of compounds targeting small GTPases is challenging [43,44]. Our data point to RBC8 being efficient and potent as a Ral inhibitor in human and mouse platelets, but that it exhibits some activity beyond just Rals, particularly in mouse platelets. It is however
-
GR activity prevents GSSG overaccumulation by reducing this
2022-04-16
GR activity prevents GSSG overaccumulation by reducing this molecule to GSH (Kranner et al., 2006). High GR activity seems to be essential for undisturbed seed germination as GR and other enzymatic antioxidants maintain sunflower (Helianthus annuus L.) seeds vigour (Bailly et al., 2002). Germination
-
Our study has strengths and limitations
2022-04-16
Our study has strengths and limitations. We believe we are the 1st to report a novel model of secondary hypogonadism. Several animal models for hypogonadotropic hypogonadism (kisspeptin and the kisspeptin receptor knockout) exist but we are unaware of animal models of secondary hypogonadism with dif
-
Numerous stimuli lead to inactivation of GSK
2022-04-16
Numerous stimuli lead to inactivation of GSK-3, including Growth Factors such as EGF (Epidermal Growth Factor), PDGF (Platelet-Derived Growth Factor), BDNF (Brain-derived neurotrophic factor), IGF (Insulin-like growth factor) and insulin (Beaulieu et al., 2009, Chen and Russo-Neustadt, 2005, Cohen a
-
Several studies have proposed that high levels of KYNA
2022-04-16
Several studies have proposed that high levels of KYNA in the Tirofiban hydrochloride monohydrate contribute to cognitive dysfunctions presented by patients who suffer from schizophrenia [30], [31], [32], [33]. Considering that: (i) KYNA is a known GPR35 agonist [2], (ii) cognitive impairments in pa
14919 records 388/995 page Previous Next First page 上5页 386387388389390 下5页 Last page